Krensavage Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Krensavage Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-397,412	Closed	-$18.3M	–	17
2016 Q3	$18.3M	Buy	397,412 +867	+0.2%	+$45.2K	6.61%	9
2016 Q2	$19.9M	Buy	396,545 +2,026	+0.5%	+$108K	7.18%	5
2016 Q1	$21.1M	Buy	394,519 +1,822	+0.5%	+$107K	7.57%	5
2015 Q4	$25.8M	Buy	392,697 +19,635	+5%	+$1.21M	8.22%	4
2015 Q3	$21.1M	Buy	373,062 +63,100	+20%	+$4.09M	7.62%	4
2015 Q2	$18.3M	Buy	309,962 +61,762	+25%	+$3.81M	6.91%	4
2015 Q1	$15.5M	Buy	248,200 +29,000	+13%	+$1.69M	7.04%	4
2014 Q4	$12.6M	Buy	+219,200	New	+$12.2M	7.02%	5

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Krensavage Asset Management's TEVA Position: Q4 2016 in Review

Krensavage Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 397,412 shares — an estimated $18.3M sold.

Krensavage Asset Management first reported a position in TEVA in Q4 2014 and held it in 8 quarters. The position peaked at $25.8M in Q4 2015. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Krensavage Asset Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Krensavage Asset Management sold 397,412 Teva Pharmaceuticals shares in Q4 2016, an estimated $18.3M.
Krensavage Asset Management first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 8 quarters.
Krensavage Asset Management's Teva Pharmaceuticals position peaked at $25.8M in Q4 2015.
738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Krensavage Asset Management's 13F filing for Q4 2016, filed 13 Feb 2017.